Aclaris Therapeutics, Inc. · NASDAQ:ACRS
Aclaris Therapeutics — Investor Presentation (August 2026)
33 slides from Aclaris Therapeutics's investor presentation, August 2026
Slide 1: Corporate Overview August 2026
Corporate Overview August 2026 EMPOWERING PATIENTS THROUGH THERAPEUTIC INNOVATION
Slide 2: Disclaimer and Cautionary Note Regarding Forward-Looking Statements
Disclaimer and Cautionary Note Regarding Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be i
Slide 3: Investment Thesis: Multiple Best-in-Class Opportunities, Three Data Readouts in 2026
INVESTMENT THESIS Multiple Best-in-Class Opportunities. Three Data Readouts in 2026. One Well-Funded Story. Program | Validated Mechanism Innovation | Competitive Advantage 2026 Expected Catalyst Bosakitug (ATI-045) 70x more potent than tezepelumab. Phase 2 topline results Anti-TSLP MAb | Validated
Slide 4: Diversified I&I Development Pipeline
DEVELOPMENT OVERVIEW Diversified I&I Development Pipeline Preclinical Phase 1 Phase 2 Phase 3 Bosakitug (ATI-045) Atopic Dermatitis TSLP mAb Phase 2: Enrollment complete (moderate-to-severe) Subcutaneous Atopic Dermatitis BIOLOGICS (EASI >21) Phase 1b: Ongoing ATI-052 Asthma TSLP x IL-4R BsAb Phase
Slide 5: 2H 2026: Key Near Term I&I Catalysts
CORPORATE MILESTONES 2H 2026: Key Near Term I&I Catalysts 2H 2026 Bosakitug (ATI-045) Phase 2 AD topline TSLP mAb results (4Q) Subcutaneous Atopic dermatitis (AD) BIOLOGICS Phase 1b POC topline D57 results (2H) ATI-052 Phase 1b POC topline TSLP x IL-4R BsAb D29 results (2H) Subcutaneous Asthma Phase
Slide 6: Substantial Opportunities in I&I for Innovative Drugs
COMMERCIAL STRATEGY Substantial Opportunities in I&I for Innovative Drugs Dual Approach to Addressing Significant Gaps in Unsatisfied I&I Indications Opportunities for Kinase Inhibitors Opportunities for Biologics • Faster onset, durable, consistent effect • Potential first line therapy • Broader ef
Slide 7: Over 1B People Live with Addressable I&I Diseases
COMMERCIAL OVERVIEW Over 1B People Live with Addressable I&I Diseases U.S. Global Patients Patients Atopic dermatitis (AD) 26M 204M Dermatology Alopecia areata 6.7M 160M Th1, Th2, and Th17 Vitiligo 2-3M 70M drive dermatological, Lichen planus 0.6M 12M respiratory, and gastrointestinal (GI) Respirato
Slide 8: Market Expansion Over Time
COMMERCIAL OVERVIEW Market Expansion Over Time New Entrants Drive Significant Market Growth and Rapid Adoption Evolution of Psoriasis Market Evolution of TNFα Market 8M US patients 125M worldwide 2025 Total Sales ~3M active patients 30 $28B 60 2022 total sales (peak): $48.5B 25 50 ~4.5M active patie
Slide 9: Therapeutic Inertia in I&I Indications Like AD
COMMERCIAL OVERVIEW Therapeutic Inertia in I&I Indications Like AD Lack of Optimal Symptom Control Provides Significant Opportunity for Novel Therapies Percentage of AD patients not achieving treatment Percentage of AD patients not achieving treatment targets for Itch targets for skin clearance 100%
Slide 10: Targeting TSLP with Potential Best-in-Class Biologics
Targeting TSLP with Potential Best-in-Class Biologics Bosakitug (ATI-045) and ATI-052 Atopic, Respiratory and Immune- Mediated Disorders
Slide 11: Targeting Thymic Stromal Lymphopoietin (TSLP)
TARGET VALIDATION: TSLP Targeting Thymic Stromal Lymphopoietin (TSLP) Master Regulator of Inflammation and Immune Response TSLP: Master upstream regulator of inflammation • At the barrier surfaces of skin and the respiratory/ GI tract • Drives eosinophilic and neutrophilic inflammation and acts on a
Slide 12: Bosakitug and ATI-052: Long Residence Time
NONCLINICAL VALIDATION Bosakitug and ATI-052: Long Residence Time Lower Dissociation Rate = Potential Best-in-Class Residence Time Residence Time Dissociation of TSLP from mAbs (TR-FRET) (Hours) ATI-052 ATI-052 Bosakitug and ATI-052 demonstrate very slow dissociation kinetics from TSLP Residence tim
Slide 13: ATI-052: Potential Best-in-Class Bispecific mAb
STRUCTURAL VALIDATION ATI-052: Potential Best-in-Class Bispecific mAb Effective Dual Binding of TSLP and IL-4Rα Provides First-Line Potential Binds Anti-TSLP Binds Anti-IL4Rα Designed to inhibit TSLP upstream of the Th2 cascade Designed to inhibit immune cells Retains dissociation kinetics, residenc
Slide 14: ATI-052 vs Dupilumab + Tezepelumab
NONCLINICAL VALIDATION ATI-052 vs Dupilumab + Tezepelumab ATI-052 Demonstrates Greater Potency than mAb Combination ATI-052 Anti-TSLP/IL-4Rα Tezepelumab + Dupilumab Anti-TSLP Anti-IL-4Rα ATI-052 Combines Two Validated Blockbuster Mechanisms: Potential to Raise Efficacy Ceiling Substantially More Pot
Slide 15: ATI-052: Potential Extended Dosing
CLINICAL RESULTS: PHASE 1A SAD/MAD TRIAL ATI-052: Potential Extended Dosing All Placebo SAD Cohort 1 (30 mg) SAD Cohort 2 (120 mg) SAD Cohort 3 (360 mg) SAD Cohort 4 (720mg) MAD Cohort 1 (240 mg) MAD Cohort 2 (480 mg) Weeks Weeks Sustained, complete / near complete inhibition observed for Sustained,
Slide 16: Favorable Tolerability and Safety Profile of ATI-052
CLINICAL RESULTS: PHASE 1A SAD/MAD TRIAL Favorable Tolerability and Safety Profile of ATI-052 Provides Confidence in Continued Development • Low rate of drug related treatment emergent adverse events; predominantly Grade 1 • No SAEs; no adverse events led to study discontinuation • No Grade 3 drug-r
Slide 17: ATI-052: Next Steps and Near-Term Catalysts
CLINICAL STRATEGY ATI-052: Next Steps and Near-Term Catalysts Positive SAD/MAD Results Validate ATI-052; Program Rapidly Advancing Phase 1 Complete HV: SAD/MAD Ongoing / Next Steps Phase 1b POC Phase 1b POC Ongoing Atopic dermatitis Asthma Ongoing • Phase 1b Asthma and AD POC trials ongoing; dosing
Slide 18: Bosakitug: Improvements in Efficacy Measures
CLINICAL RESULTS: PHASE 2a MONOTHERAPY POC TRIAL (US) Bosakitug: Improvements in Efficacy Measures Validates Potential Best-in-Class Potency • Significant improvement in disease severity (EASI) • Sustained response after last dose (week 24) • Favorable safety and tolerability profile Week 26 results
Slide 19: Bosakitug: Next Steps and Near-Term Catalysts
CLINICAL STRATEGY Bosakitug: Next Steps and Near-Term Catalysts Competitively Positioned as Potential Best-in-Class TSLP mAb Phase 1 Complete HV: SAD/MAD Phase 2a Ongoing / Next Steps Atopic dermatitis Complete • Placebo-controlled Phase 2 trial in moderate-to-severe AD ongoing; Top Enrollment compl
Slide 20: Targeting ITK with Novel Potential Best-in-Class Oral Inhibitors
Targeting ITK with Novel Potential Best-in-Class Oral Inhibitors Modzatinib (ATI-2138) and Selective ITK Inhibitors
Slide 21: Diversified I&I Development Pipeline
DEVELOPMENT OVERVIEW Diversified I&I Development Pipeline Preclinical Phase 1 Phase 2 Phase 3 Bosakitug (ATI-045) Atopic Dermatitis TSLP mAb Phase 2: Enrollment complete (moderate-to-severe) Subcutaneous Atopic Dermatitis BIOLOGICS (EASI >21) Phase 1b: Ongoing ATI-052 Asthma TSLP x IL-4R BsAb Phase
Slide 22: ITK Inhibition: Important in I&I Pathways
TARGET VALIDATION: ITK ITK Inhibition: Important in I&I Pathways Comparative Impact of ITK Inhibition Validates Potential Broad Applicability • ITK is a nonredundant kinase downstream of the T-cell receptor (TCR) • Drives the differentiation, proliferation and activation of TH1, TH2 and TH17 cells B
Slide 23: ITK Validated as Therapeutic Target
TARGET VALIDATION: ITK ITK Validated as Therapeutic Target Potential for Best-in-Class Positioning of Aclaris ITK Inhibitors Therapeutic Potential of ITK Aclaris ITK Franchise clinically validated: Soquelitinib (CPI-818) Highly Differentiated, Best-in-Class Potential 8 Weeks Higher Potency Lower Dru
Slide 24: Modzatinib (ATI-2138)
DEVELOPMENT STRATEGY Modzatinib (ATI-2138) Oral Small Molecule Covalent ITK & JAK3 Inhibitor for I&I Disease IL2 • Unique dual pharmacology with best-in-class potential; IL4 APC γc cytokines IL7 provides mechanistic match for diseases like lichen planus IL9 IL15 IL21 • Investigational oral compound
Slide 25: Compelling Efficacy Results in Atopic Dermatitis
CLINICAL RESULTS: MODZATINIB PHASE 2A OL TRIAL Compelling Efficacy Results in Atopic Dermatitis Mean Change in PP-NRS* Week 12: 61% mean improvement in EASI score (median = 77%) 0 % Change vs Baseline Rapid response after four weeks of Tx* 20 * • BSA 64% (p<0.001) ** 40 ** ** • EASI 77% (p<0.001) **
Slide 26: Lichen Planus and Unmet Medical Need
Lichen Planus and Unmet Medical Need
Slide 27: Lichen Planus
DEVELOPMENT STRATEGY Lichen Planus An Unaddressed Chronic, Inflammatory, Immune-Mediated Disorder Multiple impactful clinical subtypes Most common are erosive mucosal (oral), cutaneous, and lichen planopilaris Typical symptoms are debilitating Include pain, sores, severe itch, scales/plaques, hair l
Slide 28: Modzatinib: Unique "Bispecific-Like" Mechanism
DEVELOPMENT STRATEGY Modzatinib: Unique “Bispecific-Like” Mechanism First & Only Known Drug Inhibiting TCR Activation Upstream + Effector Cytokines Downstream ITK Inhibition Inhibition of T Cell Receptor (TCR) Inhibition of Cytokine Signaling Signaling (Signal 1) (Signal 3) • Inhibition of auto-anti
Slide 29: Lichen Planus is a Large and Unsatisfied Market
DEVELOPMENT STRATEGY Lichen Planus is a Large and Unsatisfied Market Significant “White Space” Opportunity for Modzatinib • Prevalence of between 0.1% and 1.0% of the population – Up to 40% of patients seek treatment despite no FDA-approved targeted therapeutic interventions – ~25% of patients have
Slide 30: ATI-9494: Potential Best-in-Class Potency Against ITK
NONCLINICAL VALIDATION ATI-9494: Potential Best-in-Class Potency Against ITK Strategically Positioned as Most Potent and Selective Next Gen ITK Inhibitor Most potent ITK-selective inhibitor in development No JAK3 engagement at pharmacologically relevant doses Highest Potency in HWB Robust Target Eng
Slide 31: ITK Program: Next Steps and Near-Term Catalysts
CLINICAL STRATEGY ITK Program: Next Steps and Near-Term Catalysts Potential Best-in-Class ITK Inhibitor Franchise Rapidly Advancing Modzatinib ITK Inhibitors Severe Hair Loss Phase 2a ATI-9494 Selective ITK Inhibitor Complete (murine) Complete Atopic Dermatitis Alopecia universalis IND-Enabling IND-
Slide 32: Continued Clinical Momentum in 2026 & 2027
CORPORATE STRATEGY: COMMITMENT TO THERAPEUTIC INNOVATION Continued Clinical Momentum in 2026 & 2027 Three Clinical Programs Ongoing; Next IND Expected in 2026 ATI-052 Cash runway Enrollment ongoing in Bosakitug (ATI-045) expected to enable asthma and AD POCs Enrollment in Phase 2 in AD development o
Slide 33: Corporate Overview August 2026
Corporate Overview August 2026 EMPOWERING PATIENTS THROUGH THERAPEUTIC INNOVATION
Aclaris Therapeutics — Investor Presentation (August 2026) on 6ix